malignant pleural effusion in platinum-resistant lung cancer
Conditions
Interventions
Group A:Methotrexate delivered vesicles
Group B:Restructured human interleukin-2
Sponsors
Anhui Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Stage IV lung cancer (the eighth edition of UICC/AJC staging) confirmed by histopathology, combined with malignant pleural effusion, and requires closed thoracic drainage; 2. Those who have experienced at least platinum-containing chemotherapy in the past and failed; 3. Age: 18 – 75 years old; male or female; 4. ECOG PS: 0 – 2 points; 5. Expected survival period >=3 months; 6. Voluntarily join the study, sign the informed consent form, have good compliance, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Women who are breastfeeding, pregnant or planning to become pregnant; 2. Allergic constitution and various drug allergies; 3. Subjects with severe infection that cannot be controlled in a short period of time; 4. Cognitive dysfunction; 5. Subjects who participated in another interventional clinical trial (clinical study) within 4 weeks before enrollment and were treated with medication, or who intended to participate in another interventional clinical trial (clinical study) throughout the study period. examinee; 6. The researcher believes that the subjects are not suitable to participate in this study due to various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Safety; | — |
Countries
China
Contacts
Public ContactShi Qingming
Anhui Chest Hospital
Outcome results
None listed